Cadila Healthcare rose 1.04% to Rs 266.90 after the US drug regulator completed its inspection at the company's Ahmedabad plant.
In an exchange filing made after market hours yesterday, the company informed that the USFDA inspected the manufacturing facility of Alidac Pharmaceuticals, the company's wholly-owned subsidiary, located at SEZ, Ahmedabad from 27 January 2020 to 4 February 2020. At the end of the inspection, no observation (483) is issued.
The site manufactures oncology injectables for the regulated markets.
The drug maker will declare its third quarter earnings today.
Cadila Healthcare is headquartered in Ahmedabad, India, and ranks 4th in the Indian pharmaceutical industry. The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
